The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

Ozempic, chemically known as semaglutide, is now the first approved treatment in Canada for type 2 diabetes and to slow ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

NEW YORK — (AP) — Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from ...

Viking Therapeutics' weight-loss pill trial results underwhelmed, causing a sharp decline in shares. Meanwhile, Novo Nordisk's liver disease approval for Wegovy uplifted its stock. European corporate ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...

Recent developments in weight-loss treatments have impacted the market significantly. Viking Therapeutics' new pill showed ...

When Opill became available a year ago, public health experts anticipated it would benefit women without health insurance and those residing in rural areas. The goal was to boost access to ...

Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver ...

Wall Street held near its record heights Monday, ahead of a week likely to be dominated by updates from the head of the ...